Klassen Preston 4
4 · Regulus Therapeutics Inc. · Filed Jun 12, 2023
Insider Transaction Report
Form 4
Klassen Preston
DirectorPresident & Head of R & D
Transactions
- Award
Stock Option (Right to Buy)
2023-06-12+350,000→ 350,000 totalExercise: $1.46Exp: 2033-06-11→ Common Stock (350,000 underlying)
Footnotes (1)
- [F1]25% of the shares vest one year following the date of grant and the remainder of the shares vest in 36 equal installments on a monthly basis thereafter, such that the option is fully vested three years following the date of grant, subject to the reporting person's continuous service.